- Home
- UWMC vs AVBP Comparison
UWMC vs AVBP Comparison
Compare UWMC & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- AVBP
- Stock Information
- Founded
- UWMC 1986
- AVBP 2021
- Country
- UWMC United States
- AVBP United States
- Employees
- UWMC N/A
- AVBP N/A
- Industry
- UWMC Finance: Consumer Services
- AVBP
- Sector
- UWMC Finance
- AVBP
- Exchange
- UWMC Nasdaq
- AVBP NYSE
- Market Cap
- UWMC 825.8M
- AVBP 862.8M
- IPO Year
- UWMC N/A
- AVBP 2024
- Fundamental
- Price
- UWMC $4.30
- AVBP $20.77
- Analyst Decision
- UWMC Hold
- AVBP Strong Buy
- Analyst Count
- UWMC 8
- AVBP 8
- Target Price
- UWMC $6.75
- AVBP $39.00
- AVG Volume (30 Days)
- UWMC 7.3M
- AVBP 487.8K
- Earning Date
- UWMC 08-05-2025
- AVBP 08-13-2025
- Dividend Yield
- UWMC 9.32%
- AVBP N/A
- EPS Growth
- UWMC N/A
- AVBP N/A
- EPS
- UWMC N/A
- AVBP N/A
- Revenue
- UWMC $2,486,541,000.00
- AVBP N/A
- Revenue This Year
- UWMC $11.32
- AVBP $85.82
- Revenue Next Year
- UWMC $22.84
- AVBP N/A
- P/E Ratio
- UWMC N/A
- AVBP N/A
- Revenue Growth
- UWMC 10.39
- AVBP N/A
- 52 Week Low
- UWMC $3.80
- AVBP $15.47
- 52 Week High
- UWMC $9.74
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- UWMC 52.14
- AVBP 39.60
- Support Level
- UWMC $4.06
- AVBP $20.00
- Resistance Level
- UWMC $4.40
- AVBP $23.27
- Average True Range (ATR)
- UWMC 0.16
- AVBP 1.51
- MACD
- UWMC 0.03
- AVBP -0.49
- Stochastic Oscillator
- UWMC 77.69
- AVBP 13.28
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.